CLINICAL TRIALS PROFILE FOR VANCERIL DOUBLE STRENGTH
✉ Email this page to a colleague
All Clinical Trials for VANCERIL DOUBLE STRENGTH
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00489203 ↗ | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | Completed | Fred Hutchinson Cancer Research Center | Phase 2 | 2007-04-01 | RATIONALE: Beclomethasone dipropionate may be effective in preventing acute graft-versus-host disease in patients undergoing a stem cell transplant for hematologic cancer. PURPOSE: This randomized phase II trial is studying how well beclomethasone dipropionate works in preventing acute graft-versus-host disease in patients undergoing a donor stem cell transplant for hematologic cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VANCERIL DOUBLE STRENGTH
Condition Name
Condition Name for VANCERIL DOUBLE STRENGTH | |
Intervention | Trials |
Stage I Adult Diffuse Mixed Cell Lymphoma | 1 |
Chronic Myelomonocytic Leukemia | 1 |
Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | 1 |
Noncontiguous Stage II Grade 2 Follicular Lymphoma | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for VANCERIL DOUBLE STRENGTH
Trials by Country
Clinical Trial Progress for VANCERIL DOUBLE STRENGTH
Clinical Trial Phase
Clinical Trial Sponsors for VANCERIL DOUBLE STRENGTH
Sponsor Name